Related Experiment Videos
Pulmonary hemorrhage in systemic lupus erythematosus
L A Barile1, L J Jara, F Medina-Rodriguez
1Hospital de Especialidades, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Lupus
|January 1, 1997
Summary
Systemic lupus erythematosus (SLE) patients with pulmonary hemorrhage (PH) face severe respiratory failure. Early, massive methylprednisolone treatment improved survival rates in this high-risk SLE complication.
Area of Science:
- Rheumatology
- Pulmonology
- Critical Care Medicine
Background:
- Pulmonary hemorrhage (PH) is a severe complication of systemic lupus erythematosus (SLE).
- Patients with SLE-associated PH often present with critical respiratory failure.
Purpose of the Study:
- To evaluate the clinical characteristics and survival rates of SLE patients experiencing pulmonary hemorrhage.
- To identify effective treatment strategies for SLE-associated PH.
Main Methods:
- A retrospective study of 34 SLE patients with PH from a cohort of 630 patients.
- Analysis of three treatment regimens: oral prednisone, conventional dose methylprednisolone, and massive dose methylprednisolone.
- Correlation of survival rates with treatment regimens and timing of intervention.
Main Results:
- The overall survival rate for SLE patients with PH was 38.2%.
- Patients receiving massive methylprednisolone (> 4 g) showed improved survival.
- Early treatment initiation (within 48 hours of symptom onset) was associated with better outcomes.
Conclusions:
- Pulmonary hemorrhage in SLE is associated with a high mortality rate.
- Aggressive and timely treatment, particularly with high-dose methylprednisolone, is crucial for improving survival in SLE-associated PH.